<DOC>
	<DOCNO>NCT00383929</DOCNO>
	<brief_summary>In study intend compare blood pressure lower effect combination candesartan cilexetil ( candesartan ) 32 mg hydrochlorothiazide ( HCT ) 25 mg combination candesartan 32 mg HCT 12.5 mg candesartan 32 mg alone patient whose blood pressure well control candesartan 32 mg monotherapy . The Primary Objectives compare sit BP lower effect candesartan/HCT 32/25 mg candesartan/HCT 32/12.5 mg candesartan 32 mg , respectively .</brief_summary>
	<brief_title>Antihypertensive Efficacy Safety Candesartan/HCT 32/12.5 32/25 mg Comparison With Candesartan 32 mg</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients eligible enrolment study ( Visit 1 ) fulfil follow criterion : Provision sign Informed Consent Primary hypertension , untreated treat maximum 2 antihypertensive drug , patient physician willing withdraw enrolment change candesartan monotherapy Mean sit DBP 90114 mmHg Patients eligible randomisation ( Visit 4 ) fulfil follow criterion : Mean sit DBP 90114 mmHg treatment candesartan 32 mg monotherapy ( 2 week candesartan 16 mg 6 week candesartan 32 mg monotherapy ) . The runin period shorter 8 week . Involvement plan conduct study ( applies AstraZeneca staff , CRO staff staff investigational centre ) Pregnant lactate woman , woman childbearing potential practising adequate method contraception eg , intrauterine device , oral contraception progesterone implant verify negative pregnancy test Visit 1 Secondary malignant hypertension Sitting SBP 180 mmHg Patients treat candesartan 16 mg combination diuretic candesartan 32 mg without additional antihypertensive treatment Myocardial infarction , stroke , coronary bypass surgery transient ischaemic attack within 6 month enrolment Angina pectoris require treatment shortacting nitrate Chronic use NSAIDs Aortic mitral valve stenosis Cardiac failure require treatment Cardiac arrhythmia require treatment Gout Renal artery stenosis kidney transplantation Intravascular volume depletion Hypersensitivity component investigational product Concomitant disease may interfere assessment patient Past present alcohol drug abuse , condition associate poor compliance Chronic liver disease know liver enzyme value three time upper limit reference range SASAT SALAT Concomitant previous treatment investigational drug within 20 day enrolment Previous enrolment present study Screatinine 180 μmol/l men 140 μmol/l woman Ssodium Spotassium outside reference range Less 85 % compliance study medication runin phase</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Blood pressure reduction</keyword>
	<keyword>combination therapy</keyword>
	<keyword>candesartan cilexetil</keyword>
	<keyword>hydrochlorothiazide</keyword>
</DOC>